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Background: A phase III trial demonstrated an overall survival advantage with the addition of vinflunine to best supportive care
(BSC) in platinum-refractory advanced urothelial cancer. We subsequently examined the impact of an additional 2 years of survival
follow-up and evaluated the influence of first-line platinum therapy on survival.
Methods: The 357 eligible patients from the phase III study were categorised into two cohorts depending on prior cisplatin
treatment: cisplatin or non-cisplatin. Survival was calculated using the Kaplan–Meier method.
Results: The majority had received prior cisplatin (70.3%). Survival was higher in the cisplatin group (HR: 0.76; CI 95% 0.58–0.99;
P¼0.04) irrespective of treatment arm. Multivariate analysis including known prognostic factors (liver involvement, haemoglobin,
performance status) and prior platinum administration did not show an independent effect of cisplatin. Vinflunine reduced the
risk of death by 24% in the cisplatin-group (HR: 0.76; CI 95% 0.58–0.99; P¼0.04) and by 35% in non-cisplatin patients (HR: 0.65;
CI 95% 0.41–1.04; P¼0.07).
Interpretation: Differences in prognostic factors between patients who can receive prior cisplatin and those who cannot may
explain the survival differences in patients who undergo second line therapy. Prior cisplatin administration did not diminish the
subsequent benefit of vinflunine over BSC.
While metastatic urothelial cancer (UC) is generally sensitive to
chemotherapy, the majority of patients will succumb to this
disease. Cisplatin-based regimens such as gemcitabine plus
cisplatin (GC) or methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) increase survival and remain the cornerstone of
first-line treatment (von der Maase et al, 2000; Sternberg et al,
2001; von der Maase et al, 2005). In patients unfit to receive
cisplatin, regimens containing gemcitabine, carboplatin, or taxane
are often utilised (Dreicer et al, 2004; De Santis et al, 2012).
Vinflunine is a microtubule inhibitor that elicits more potent
in vivo antitumor activity than other members of the vinca
alkaloid family such as paclitaxel or docetaxel (Lobert et al, 1998;
Jean-Decoster et al, 1999; Ngan et al, 2001). Its weaker binding to
tubulin translates to potentially less neurotoxicity. Two phase II
studies in platinum refractory advanced UC patients suggested
intriguing preliminary efficacy with an objective response rate of
16–18%, a median duration of response of 6–9 months, and a
median progression-free survival (PFS) around 3 months (Culine
et al, 2006; Vaughn et al, 2009). These studies led to a phase III
randomised controlled trial executed mostly in Europe, where
vinflunine plus best supportive care (BSC) was compared with BSC
alone in 370 patients who had experienced progression during or
after first-line platinum-based chemotherapy (Bellmunt et al,
2009). A non-statistically significant 2-month increase in the
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6.9 months with the addition of vinflunine (HR 0.88; 95% CI,
0.69–1.12, P¼0.29 (L00070 IN 302 trial) was observed. It is
important to note that the ITT analysis may have been clouded by
the inclusion of patients with protocol deviations. A pre-planned
analysis in eligible patients that excluded the deviation cases
confirmed statistical significance, with the median OS for
vinflunine plus BSC being 6.9 months compared with BSC alone
at 4.3 months (P¼0.04) and led to its approval by the European
Medicines Agency (EMEA) (Bellmunt et al, 2009).
During the EMEA assessment of the vinflunine submission, the
question of whether prior platinum therapy had an impact on OS
was raised. This query stemmed from a subgroup analysis of OS
stratified by prior cisplatin administration in the ITT population
(November 2006 cutoff date). This analysis suggested that the
degree of benefit elicited by vinflunine was lower in the cisplatin
group with a 9% decrease in the risk of death compared to 25% in
the non-cisplatin group (HR¼0.91 vs HR¼0.75). These results
led some to hypothesise that vinflunine might only be effective in
patients who had not received prior cisplatin. These findings
spurred us to perform an updated analysis that adjusted for an
additional 2-year survival follow-up period and incorporated a test
for interaction to evaluate the impact of the first-line platinum
therapy on overall survival when vinflunine is administered in the
second-line setting.
METHODS
Patient population. The analysis focused on the 357 eligible
patients with UC who were enroled onto the phase III randomised
controlled trial, which compared vinflunine plus BSC with BSC
alone (L00070 IN 302), with an updated median follow-up of now
45.4 months (Bellmunt et al, 2009). The ‘eligible’ population is
distinct from the ITT population, as it removes 13 patients who
had major protocol deviations as detailed in the original report.
The demographics of this patient population have been previously
described and were generally well balanced, with the exception of a
10% difference in worse performance status (PS) favouring the
control arm. Random assignment in the Phase III study was
stratified by study site and platinum-refractory status but not by
PS, which is now recognised as an important prognostic factor
(Bajorin et al, 1999; Bellmunt et al, 2010). Pretreatment clinical
and analytic factors were prospectively recorded. Type and setting
of prior therapy in both arms were also prospectively recorded. For
this current study, the eligible population was split into the
following two subsets: cisplatin (patients with prior cisplatin
administration) and non-cisplatin (patients without prior cisplatin
administration) irrespective of the phase III treatment arm they
were on in order to study the impact of prior platinum therapy.
Institutional Review Board/Ethics Committee approvals from each
institution were obtained as part of the prospective intervention
trial.
Statistical analysis. Survival was measured from the date of
random assignment to either the date of death or the last follow-
up. For this analysis, mature updated survival data were used. The
cutoff date was 30 November 2008. This update represented a
significantly longer median follow-up period of 45.5 months
compared with 22.1 months in the initial analysis. Cox propor-
tional hazards models were used to evaluate the effect of treatment
on OS. The distributions of OS were estimated using the Kaplan–
Meier method for each treatment group and were compared
between treatments by stratified log-rank tests. Subgroup analysis
was conducted according to the prior platinum administration. An
interaction term between study treatment and prior platinum
therapy evaluated whether the association between study treatment
and risk of death reduction differed according to the prior
platinum therapy. In addition, Cox multivariate analyses were
performed to take into account important prognostic factors that
have been previously identified: haemoglobin (o10gdl
 1 vs
X10gdl
 1), ECOG PS (o1 vs X1), and liver metastasis (present
vs absent).
RESULTS
Patient characteristics. Of the 357 patients enroled on the
second-line vinflunine trial, 251 received prior cisplatin (70.3%)
and 106 did not (29.7%). As expected, the most common first-line
cisplatin-based regimens were GC (48.5%) and MVAC (12.9%)
(Supplementary Online Material Table 1). The most common
regimens administered in the first-line setting for the non-cisplatin
group were carboplatin and gemcitabine.
Overall, patients in the cisplatin group tended to be younger
(median age 63 vs 69 years) and have better renal function (median
CrCl: 64 vs 55ccmin
 1) at the initiation of second-line vinflunine
(Table 1). They had better prognostic characteristics with less
frequent liver involvement (25% for cisplatin vs 43% for non-
cisplatin-treated patients, P¼0.0007) and enhanced PS as
measured by WHO-PS X1 (66% for cisplatin vs 76% for non-
cisplatin, P¼0.047) (Table 1).
Survival. When evaluating eligible patients on the trial regardless
of whether they received vinflunine or only BSC, patients who were
treated with first-line cisplatin-based chemotherapy had improved
overall survival compared with patients who did not receive first-
line cisplatin (Figure 1). Prior cisplatin reduced the risk of death by
23% compared with no prior cisplatin (stratified log-rank test
P¼0.0294). However, this significance did not persist in multi-
variate analysis when adjusted for known important prognostic
factors such as liver involvement, PS, and haemoglobin (Table 2).
Compared with the initial subgroup analysis of OS according to
prior cisplatin administration in the ITT population (November
2006 cutoff date, Table 3), in the updated analysis of the eligible
(modified ITT) population, vinflunine now significantly reduced
the risk of death by 24% with a median gain of 2.2 months in the
median OS compared with BSC in patients who received prior
cisplatin (P¼0.04, Table 4). In patients without prior cisplatin
exposure, an increase in 2.4 months in the median OS was
obtained with vinflunine, reducing the risk of death by 35%
(P¼0.07). The Kaplan–Meier curves in the cisplatin group
(Figure 2) and in the non-cisplatin group (Figure 3) illustrate the
benefit of vinflunine in terms of survival irrespective of prior
cisplatin therapy.
In order to ensure that the risk of death reduction associated
with vinflunine is the same whether or not patients received prior
cisplatin, a statistical test for interaction was conducted (Table 5).
This test was not significant (P¼0.63), confirming that the effect
of vinflunine on survival is not diminished by prior cisplatin
administration. Thus, the best estimate for vinflunine effect
adjusted on prior cisplatin use is obtained with a model, which
includes only the main potential effects of treatment group and
prior cisplatin (Table 6) (HR 0.73; 95% CI, 0.58–0.93, P¼0.009).
DISCUSSION
Subgroup analysis during the EMEA assessment of the vinflunine
submission suggested that the degree of benefit elicited by
vinflunine was lower in the cisplatin group with a 9% vs 25%
decrease in the risk of death (0.91 vs 0.75 in the non-cisplatin
group, Table 3). These results suggested that the administration of
vinflunine might only be effective in patients who had not received
Impact of prior platinum on vinflunine in UC BRITISH JOURNAL OF CANCER
www.bjcancer.com|DOI:10.1038/bjc.2013.617 2549prior cisplatin. With its longer followup time, our updated analysis
dismisses this theory but validates the generally accepted belief that
patients who are eligible for cisplatin have better outcomes.
Regardless of whether patients received vinflunine or only BSC in
the second-line setting, patients who were treated with first-line
cisplatin-based chemotherapy had improved overall survival
(Figure 1). In all patients, prior cisplatin use significantly reduced
the risk of death by 23% compared with no prior cisplatin use
(P¼0.04). These results suggest that the previous therapy with
cisplatin is important for survival in the second-line setting
irrespective of the actual second-line therapy, in the case either
vinflunine or BSC. However, the possibility of selection bias should
be stressed; in order to receive cisplatin in the first place, patients
are generally relatively ‘healthier’ with good PS and adequate end
organ function. The established prognostic factors for improved
survival include good PS and absence of visceral metastases or
anaemia (Bajorin et al, 1999; Bellmunt et al, 2010). In a
retrospective review of seven prospective second-line phase II
trials, Sonpavde et al (2013) further observed that shorter time
from prior cisplatin therapy to start of subsequent therapy also
portended worse survival in the second-line setting. In the phase
III vinflunine trial, patients who had received prior cisplatin had
overall more favourable prognostic criteria (Table 1). Further,
multivariate analysis adjusting for the validated prognostic factors
of liver involvement, PS, and haemoglobin confirmed that these
factors were more important drivers in the survival improvement
than the prior cisplatin use (Table 2). In the study by Sonpavde
et al (2013), despite a favourable trend, time from prior cisplatin
therapy did not bear out as independently significant for OS
(P¼0.066) in multivariable analysis that included PS 40, presence
of liver metastases, and haemoglobin o10. Taken together, these
results validate that metastases to the liver, poor PS, and anaemia
remain the most important criteria for survival in metastatic
platinum-pretreated urothelial carcinoma. Patients with the
triumvariate are less likely to receive cisplatin-based therapy and
as such the overall ability to get cisplatin may be a reflection of the
presence of these unfavourable markers or more aggressive disease.
Our secondary objective was to assess whether patients who
had received prior cisplatin specifically benefit from second-line
Table 1. Patient characteristics at initiation of second line vinflunine in the
eligible patients
No
Cisplatin
Prior
cisplatin Total
N (%) N (%) N (%)
Age (years) N¼106
68.85
(39.55–86.29)
N¼251
62.48
(34.58–82.92
N¼357
64.27
(34.58–86.29)
Gender
Male 85 (80.19) 194 (77.29) 279 (78.15)
Female 21 (19.81) 57 (22.71) 78 (21.85)
Refractory status
Refractory patient 11 (10.38) 34 (13.55) 45 (12.61)
Non-refractory patient 95 (89.62) 217 (86.45) 312 (87.39)
Liver involvement
No 60 (56.60) 188 (74.90) 248 (69.47)
Yes 46 (43.40) 63 (25.10) 109 (30.53)
Number of organ(s) involved
1 26 (24.53) 60 (23.90) 86 (24.09)
41 80 (75.47) 191 (76.10) 271 (75.91)
Visceral involvement
Yes 80 (75.47) 187 (74.50) 267 (74.79)
No 26 (24.53) 64 (25.50) 90 (25.21)
Lymph nodes involvement
No 42 (39.62) 88 (35.06) 130 (36.41)
Yes 64 (60.38) 163 (64.94) 227 (63.59
WHO PS
PSX1 81 (76.42) 165 (65.74) 246 (68.91)
PS¼0 25 (23.58) 86 (34.26) 111 (31.09)
Creatinine clearance
(median)
N¼105
55
(21–139)
N¼249
64.2
(23–149)
N¼354
61
(21–149)
Haemoglobin
o10gdl
 1 14 (13.21) 38 (15.14) 52 (14.57)
X10gdl
 1 92 (86.79) 213 (84.86) 305 (85.43)
Alkaline phosphatase
Missing 3 (2.83) 6 (2.39) 9 (2.52)
Abnormal 42 (39.62) 65 (25.90) 107 (29.97)
Normal 61 (57.55) 180 (71.71) 241 (67.51)
Pelvic irradiation
No 82 (77.36) 194 ((77.29) 276 (77.31)
Yes 24 (22.64) 57 (22.71) 81 (22.69)
Number of patients 106 (100) 251 (100) 357 (100)
Product-limit survival estimates
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Figure 1. Overall Survival in second-line according to prior CDDP
administration.
Table 2. Multivariate analysis of overall survival using a cox proportional
hazard model
Variables at randomisation Hazard ratio (95% CI) P-value
Prior platinum administration 0.867 (0.682–1.102) 0.2440
Liver involvement 2.199 (1.720–2.811) o0.0001
Haemoglobin 0.487 (0.357–0.663) o0.0001
WHO performance status 0.560 (0.436–0.720) o0.0001
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efficacy in these patients. Our updated analysis revealed that
vinflunine’s benefit was not restricted to the non-cisplatin
patients (Table 4). The reduction in the risk of death obtained
with vinflunine was similar in the cisplatin and non-cisplatin
arms. In all patients who received first-line cisplatin, vinflunine
elicited a median 2.2 month increase in survival compared with
patients who received BSC (6.9 vs 4.7 months, HR 0.76,
P¼0.04). This benefit equates to a significant reduction in the
risk of death by 24% compared with BSC. Similarly, in patients
who did not receive prior cisplatin, vinflunine increased OS by a
median of 2.4 months (5.8 vs 3.4 months, HR 0.65, P¼0.07),
signifying a 35% reduction in the risk of death compared with
BSC. Although the difference in OS in the non-cisplatin group
did not achieve statistical significance (P¼0.07), likely due to a
lack of power given the small patient numbers in this cohort, the
trend is clearly in favour of vinflunine. Finally, the statistical test
for interaction between prior cisplatin administration and
treatment arm (vinflunine vs BSC) is not significant, confirming
that the effect of vinflunine on the risk of death reduction is
similar regardless of prior platinum administration. As the test
Table 3. Overall survival analysis based on prior cisplatin administration – original ITT population – November 2006 cutoff date
VFLþBSC arm BSC arm
Median OS (95% CI) (months) Median OS (95% CI) (months) Hazard ratio (95% CI)
Patients with prior Cisplatin N¼170
6.9 (5.7–8.0)
N¼91
5.3 (4.3–8.2)
0.91 (0.69–1.20)
Patients without prior Cisplatin N¼83
6.0 (4.6–8.7)
N¼26
3.7 (3.1–7.1)
0.75 (0.47–1.21)
Abbreviations: BSC¼best supportive care; OS¼overall survival.
Table 4 . Overall survival analysis based on prior cisplatin administration –
eligible (modified ITT) population with updated survival follow-up – Nov
2008 cut-off date
VFLþBSC arm
Median OS
(95% CI)
(months)
BSC arm
Median OS
(95% CI)
(months)
Hazard Ratio
(95% CI)
Patients
with prior
Cisplatin
N¼167
6.9 (5.7–8.2)
N¼84
4.7 (4.1–6.8)
0.76 (0.58–0.99)
P¼0.0433
Patients
without prior
Cisplatin
N¼82
5.8 (4.2–8.2)
N¼24
3.4 (2.5–4.5)
0.65 (0.41–1.04)
P¼0.0724
Hazard
ratio (95% CI)
0.78 (0.59–1.02)
P¼0.0693
0.68 (0.42–1.08)
P¼0.0978
Abbreviations: BSC¼best supportive care; OS¼overall survival.
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Figure 2. Overall Survival in the patients treated with prior cisplatin
from the initiation of vinflunine.
1.0
0.8
0.6
0.4
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
0.2
0.0
0 10 20
Product-limit survival estimates
Censored
ARM
Best supportive care arm
Vinflunine and best supportive care arm
Overall survival in months (*)
30 40
Figure 3. Overall survival in the non-cisplatin patients from initiation of
vinflunine.
Table 5. Analysis of overall survival – model with interaction between
CDDP and ARM
Variables at randomisation Hazard ratio (95% CI) P-value
Treatment group 0.666 (0. 421–1.053) 0.0817
Prior Cisplatin 0.669 (0.424–1.057) 0.0853
Prior Cisplatin * treatment group 1.139 (0.670–1.936) 0.6307
Table 6. Analysis of overall survival – model with main effects only
Variables at randomisation Hazard ratio (95% CI) P-value
Treatment group 0.734 (0.582–0.926) 0.0090
Prior Cisplatin 0.737 (0.582–0.935) 0.0119
Impact of prior platinum on vinflunine in UC BRITISH JOURNAL OF CANCER
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death reduction with second-line vinflunine across the whole
eligible population is 22% (HR¼0.78; 95% CI, 0.61–0.99;
P¼0.04).
It should be highlighted that this study enrolled patients in
whom all the first-line chemotherapies were delivered in the
metastatic setting. However, as the majority were able to receive
cisplatin, the patient population enroled in the phase III
second-line vinflunine trial may have been a relatively healthier
patient population with likely better PS, adequate renal
function, and less comorbidities. Not surprisingly, despite that
the effect of vinflunine remains the same in terms of reduction
in the risk of death, the observed OS was lower in the patients
who had not received prior cisplatin. This observation reflects
that patients unable to receive cisplatin likely have a worse
prognosis because of a more aggressive disease biology or other
host factors and comorbidities that outweigh the efficacy of the
specific second-line therapy they receive. The absence of a
significant difference in the HRs (0.78 vs 0.68, Table 4) supports
this assertion.
This study is limited by its post-hoc nature and limitations
inherent to any retrospective analysis. Although subset analysis can
be informative, it is the only hypothesis generating, and these
results require future validation. Perhaps most importantly,
whereas vinflunine is approved in Europe, it is not approved in
the United States, and, thus, the impact of these results are limited
in applicability outside Europe.
CONCLUSIONS
This analysis confirms that vinflunine increases survival
irrespective of prior cisplatin administration. Thus, we conclude
that cisplatin administration in the first-line setting should not
direct the choice of vinflunine in the second-line setting. Previous
cisplatin use correlates with improved survival; however, upon
further multivariate analysis, this improvement may be best
attributed to those patients having more favourable prognostic
criteria such as better PS and absence of visceral metastasis or
anaemia. Vinflunine remains the only agent to demonstrate an
improvement in OS in the second-line treatment of UC and
should be accepted as the standard of care with the recognition
that the median 2-month survival benefit is modest, and the
investigation of novel agents that target driver pathways is
imperative.
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